Inside The FTC's Take On Generic Access To Branded Drugs
The Federal Trade Commission has spent the better part of a decade pressing an expansive view of antitrust law in the context of patent settlement agreements between branded and generic pharmaceutical...To view the full article, register now.
Already a subscriber? Click here to view full article